Brief: Revive Therapeutics Announces FDA Recommendation For Type C Meeting To Discuss Amended Protocol Agreement Of Phase 3 Clinical Study For Bucillamine In The Treatment Of Covid-19
22/11/2022 14:23
Nov 22 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS ANNOUNCES FDA RECOMMENDATION FOR TYPE
C
MEETING TO DISCUSS AMENDED PROTOCOL AGREEMENT OF PHASE 3
CLINICAL STUDY FOR BUCILLAMINE IN THE TREATMENT OF COVID-19
* REVIVE THERAPEUTICS - FDA HAS NOW REQUESTED ADDITIONAL
INFORMATION, WHICH WOULD INCLUDE CLINICAL DATA, FOR THEM TO
AGREE ON STUDY'S REVISED ENDPOINTS
* REVIVE THERAPEUTICS LTD - PLANS TO GO OVER WITH FDA
OVERALL
DEVELOPMENT PLAN FOR BUCILLAMINE IN COVID-19
Source text for Eikon: ID:nGNX1mF78x
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure